In this longer-term study patients who had responded to VYVANSE in the preceding 12-week open-label treatment phase were randomized to continuation of VYVANSE or placebo for up to 26 weeks of observation for relapse
My lab has been studying this for 20 years
This makes retatrutide a GLP-1/GIP/glucagon triple agonist, and the first molecule of its kind to reach advanced clinical trials
The FDA has flagged it for severe side effects
Various groups have reported on patients who initiate therapy on the GLP-1 agonists with existing diabetic retinopathy and experience progression to vision-threatening complications, according to Ehsan Rahimy, MD, principal investigator of the study and clinical assistant professor at Stanford University
And this is why medications like Ozempic, Wegovy, and Mounjaro have also been getting a lot of attention